Table 1 Sociodemographic and clinical characteristics of patients
Patients treated with AVAPS (N = 20) | Control group (N = 20) | |
|---|---|---|
Age, years | 65.8 ± 9.8 | 65.4 ± 8.4 |
Sex: Male n%) | 12 (60%) | 10 (50%) |
Body mass index (BMI) | 24.8 ± 8.4 | 25.4 ± 7.9 |
Smoking | ||
• Never | 1(5%) | 0(0%) |
• Ex-smoker | 5(25%) | 6 (30%) |
• Current smoker | 14 (70%) | 14(70%) |
Years since COPD diagnosis | 9.5 ± 7.4 | 9.7 ± 7.9 |
FEV1, L | 0.60 ± 0.16 | 0.59 ± 0.21 |
FVC, L | 2.19 ± 0.55 | 1.90 ± 0.50 |
Underlying disease | ||
Diabetes | 7(35%) | 5(25%) |
Hypertension | 6 (30%) | 8(40%) |
Dyslipidemia | 3 (15%) | 4(20%) |
Chronic kidney disease | 1 (5%) | 2 (10%) |
Coronary artery disease | 4 (20%) | 3(15%) |